Dr. Gottlieb resigned from the FDA in April after running the agency for two years. Throughout his tenure he became known for cracking down on the e-cigarette industry and trying to get a handle on the opioid crisis.
Dr. Gottlieb will serve on two committees on Pfizer’s board, regulatory and compliance and science and technology.
“I’m honored to be joining the board of directors of #Pfizer and working together with more than 90,000 Pfizer colleagues to promote medical innovation, advance patient care, and secure access to better healthcare outcomes for families around the world,” Dr. Gottlieb tweeted June 27.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
